ANDA 218088, held by Lupin Inc.. Revefenacin.
As of Nov 16, 2026, ANDA 218088 (Revefenacin), held by Lupin Inc., was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 15, 2026 | Original application | Tentative approval | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Revefenacin88UG/3ML ยท solution | Revefenacin | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters